Stay updated on Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedNo substantive changes detected; observed updates appear limited to minor UI text tweaks and the page's last updated timestamp, with core study content, eligibility criteria, primary outcomes, and locations remaining the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check38 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference1%

- Check46 days agoChange DetectedThe page shifts from detailed cancer histology terms to broader immunology-related topics and updates to a new revision (v3.1.0), removing several cancer-specific classifications (v3.0.2).SummaryDifference2%

- Check60 days agoChange DetectedUpdated the page to Revision v3.0.2 from v3.0.1, and removed the old 'Back to Top' element.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.SummaryDifference0.1%

- Check74 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as specific medical terms related to ovarian cancer, while removing outdated location details and certain genetic resources.SummaryDifference4%

Stay in the know with updates to Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab ± Ipilimumab in Ovarian Cancer Clinical Trial page.